Via The Life Science Report:

Expert Comments:

Alan Ridgeway, Paradigm Capital (10/1/13) "Oncolytics Biotech Inc. is well positioned as the market leader in virus-medicated cancer therapy; its lead product, REOLYSIN, has produced impressive clinical results to date in multiple indications and has the potential to revolutionize the treatment of cancer. We believe a number of catalysts will occur in the next three months: 1) survival data from its phase 3 trial in head and neck cancer; 2) the release of mature lung cancer data from 2 separate phase 2a trials; and 3) potential releases of data from randomized trials in pancreatic and ovarian cancer."